399 related articles for article (PubMed ID: 17180125)
1. Rationale for the administration of acellular pertussis vaccine to parents of infants in the neonatal intensive care unit.
Shah S; Caprio M; Mally P; Hendricks-Munoz K
J Perinatol; 2007 Jan; 27(1):1-3. PubMed ID: 17180125
[TBL] [Abstract][Full Text] [Related]
2. Administration of tetanus, diphtheria, and acellular pertussis vaccine to parents of high-risk infants in the neonatal intensive care unit.
Dylag AM; Shah SI
Pediatrics; 2008 Sep; 122(3):e550-5. PubMed ID: 18762489
[TBL] [Abstract][Full Text] [Related]
3. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
4. Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.
Bechini A; Tiscione E; Boccalini S; Levi M; Bonanni P
Vaccine; 2012 Jul; 30(35):5179-90. PubMed ID: 22709953
[TBL] [Abstract][Full Text] [Related]
5. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
Gidengil CA; Sandora TJ; Lee GM
Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
[TBL] [Abstract][Full Text] [Related]
6. [Time for booster doses against whooping cough for 10-year-old children].
Carlsson RM; Ekholm L; Gothefors L; Granström M; Trolin I; Tegnell A
Lakartidningen; 2005 Aug 29-Sep 4; 102(35):2394-8. PubMed ID: 16184889
[TBL] [Abstract][Full Text] [Related]
7. Potential impact of acceleration of the pertussis vaccine primary series for infants.
Shinall MC; Peters TR; Zhu Y; Chen Q; Poehling KA
Pediatrics; 2008 Nov; 122(5):1021-6. PubMed ID: 18977982
[TBL] [Abstract][Full Text] [Related]
8. Response to an education program for parents about adult pertussis vaccination.
Iroh Tam PY; Visintainer P; Fisher D
Infect Control Hosp Epidemiol; 2009 Jun; 30(6):589-92. PubMed ID: 19419326
[TBL] [Abstract][Full Text] [Related]
9. Rationale for use of Tdap booster vaccines for adolescent immunization: overview of efficacy, safety, and clinical use.
Hitchcock WP
Clin Pediatr (Phila); 2006 Nov; 45(9):785-94. PubMed ID: 17041165
[TBL] [Abstract][Full Text] [Related]
10. Re-emergence of diphtheria and pertussis: implications for Nigeria.
Sadoh AE; Oladokun RE
Vaccine; 2012 Nov; 30(50):7221-8. PubMed ID: 23102975
[TBL] [Abstract][Full Text] [Related]
11. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
Greer AL; Fisman DN
Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
[TBL] [Abstract][Full Text] [Related]
12. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
Gustafsson L; Hessel L; Storsaeter J; Olin P
Pediatrics; 2006 Sep; 118(3):978-84. PubMed ID: 16950988
[TBL] [Abstract][Full Text] [Related]
14. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
Wilson TR
J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
[TBL] [Abstract][Full Text] [Related]
15. Pertussis immunization patterns in special care nursery graduates.
Ruiz P; Nathanson R; Kastner T
J Dev Behav Pediatr; 1991 Feb; 12(1):38-41. PubMed ID: 2016401
[TBL] [Abstract][Full Text] [Related]
16. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations.
Gardner P
Clin Infect Dis; 1999 Jun; 28 Suppl 2():S131-5. PubMed ID: 10447031
[TBL] [Abstract][Full Text] [Related]
17. Pertussis--United States, 2001-2003.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2005 Dec; 54(50):1283-6. PubMed ID: 16371944
[TBL] [Abstract][Full Text] [Related]
18. Administration of inactivated trivalent influenza vaccine to parents of high-risk infants in the neonatal intensive care unit.
Shah SI; Caprio M; Hendricks-Munoz K
Pediatrics; 2007 Sep; 120(3):e617-21. PubMed ID: 17766502
[TBL] [Abstract][Full Text] [Related]
19. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
20. Safety of DTaP-IPV-HIb-HBV hexavalent vaccine in very premature infants.
Faldella G; Galletti S; Corvaglia L; Ancora G; Alessandroni R
Vaccine; 2007 Jan; 25(6):1036-42. PubMed ID: 17088013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
